After a large jump of clinical news was reported in September, the momentum has continued throughout October, with an 8% increase over the prior month.
Wellcome Leap has launched its first program, dedicating $50 million to help develop human tissues, organoids and full organs. The Human Organs, Physiology and Engineering (HOPE) program is looking to bring biologists and engineers together to develop both therapeutic organs as well as organs that can be used in vitro to help discover and develop new medications.
If not for the coronavirus and a highly contested U.S. presidential election, 2020 might just be the year of the biopharma financing. With 1,320 transactions tallied and the amount raised hitting $115.77 billion, the year represents the highest volume and value for the industry to date.
When entrepreneurs and emerging businesses raise seed capital for a new business or generate funding for business growth, they often turn to the exempt offering framework under the Securities Act. However, when doing so, they are faced with a confusing and complex system that must be navigated. To simplify the process, the SEC has announced that it is amending its rules that govern offering exemptions, which small and medium-sized business rely on to raise capital.
The dramatic increase in COVID-19 infections in Europe and the U.S., combined with information overload surrounding the lead up to the Nov. 3 contentious U.S. presidential election, was more than enough to send investors to the sidelines in October.
RSS
